What's breaking now, across thousands of outlets.
(MedPage Today) -- The FDA approved the oral fibroblast growth factor receptor 2 (FGFR2) inhibitor lirafugratinib (Lyrfigtu) for adults with previously treated cholangiocarcinoma (CCA) with FGFR2 fusion or other rearrangements, the agency announced...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.
Pressed by lawmakers on Thursday, Trump’s pick as the next FDA chief said she’d “follow the law” on key decisions and work to speed early drug research.
Attention has turned to how mortality and vaccination rates compare to "one of the most contagious diseases" there is.
Grail’s Galleri test costs $1,000 and promises comprehensive early-stage screening for more than 50 types of cancer.
A new analysis of nearly 150,000 food and beverage products launched in the United States over the past decade found that products bearing health-related claims are not consistently healthier and are…
University of South Florida researchers have discovered a previously unknown vulnerability in Plasmodium vivax (P. vivax), a malaria parasite that infects millions of people in Central and South…
Patient groups decry ‘scandalous’ delays as four integrated care boards take step due to soaring demand for diagnoses NHS bodies are forcing people with suspected attention deficit hyperactivity…
